Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
393
datasets available to search
ShareScore release 0.9.0
Dataset results
393 results for “mRNA vaccine”
Andes virus mRNA vaccines: comparison of unmodified and modified mRNA platforms [VDJ-seq]
GEO Series GSE240063. Mus musculus. 16 samples. Type: Other.
Dosing interval is a major factor determining the quality of T cells induced by SARS-CoV-2 mRNA and adenoviral vaccines
GEO Series GSE303984. Homo sapiens. 102 samples. Type: Expression profiling by high throughput sequencing; Other.
mRNA COVID-19 vaccine elicits potent adaptive immune response without the acute inflammation of SARS-CoV-2 infection [HC]
GEO Series GSE247916. Homo sapiens. 6 samples. Type: Expression profiling by high throughput sequencing; Other.
An mRNA vaccine induces antimycobacterial immunity by activating DNA damage repair and autophagy
GEO Series GSE269547. Danio rerio. 6 samples. Type: Expression profiling by high throughput sequencing.
Heterologous immunization with inactivated vaccine followed by mRNA booster elicits strong humoral and cellular immune responses against the SARS-CoV-2 Omicron variant
<p>The recent emergence of the Omicron variant has raised concerns on vaccine efficacy and the urgent need to study more efficient vaccination strategies. Here we evaluated the effect of an mRNA vaccine booster on immunogenicity in individuals vaccinated with two doses of inactivated vaccine. We observed that an mRNA vaccine booster significantly increased the plasma level of specific antibodies that bind to the receptor-binding domain (RBD) or the spike (S) ectodomain (S1+S2) of both the G614 and the Omicron variants, compared to two doses of homologous inactivated vaccine. The level of RBD- and S-specific IgG antibodies and virus neutralization titers against variants of concern in the heterologous vaccination group were similar to that in individuals receiving three doses of homologous mRNA vaccine or a boost of mRNA vaccine after infection, but markedly higher than that in individuals receiving three doses of a homologous inactivated vaccine. Moreover, this heterologous vaccination regime significantly enhanced the RBD-specific memory B cell response and S1-specific T cell response compared to two or three doses of homologous inactivated vaccine. Our study demonstrates that an mRNA vaccine booster in individuals vaccinated with inactivated vaccines can be highly beneficial, as it markedly increases the humoral and cellular immune responses against the virus, including the Omicron variant</p>
Comparative immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens
<p>Multiple formulations and technologies for vaccinating against SARS-CoV-2 exist but how the use of these in homologous or heterologous format impacts immunogenicity is far from clear. Here the authors compare a range of heterologous and homologous SARS-CoV-2 vaccination strategies and assess the induced humoral and cellular immune response.</p> <p>The following heterologous and homologous vaccination regimens were tested for immunogenicity and reactogenicity in a in a convenience cohort of 331 healthy individuals. </p> <p>ChAdOx1-nCoV-19 followed by BNT162b2 (n=66)</p> <p>ChAdOx1-nCoV-19 followed by mRNA-1273 (n=101)</p> <p>BNT162b2 followed by BNT162b2 (n=43)</p> <p>mRNA-1273 followed by mRNA-1273 (n=59)</p> <p>ChAdOx1-nCoV-19 followed by ChAdOx1-nCoV-19 (n=62)</p>
Adaptive immune responses to Omicron BA.4/BA.5-containing bivalent mRNA booster vaccination
<p>This repository contains the immunoSEQ T-cell receptor (TCR) and B-cell receptor (BCR) repertoire data used in the manuscript titled "Adaptive immune responses to Omicron BA.4/BA.5-containing bivalent mRNA booster vaccination". This data set is composed of the TCR/BCR repertoire clonotype sequences and abundances derived from human peripheral blood mononuclear cell (PBMC) samples sorted for CD4, CD8 and CD19 before and after bivalent COVID mRNA booster vaccination. In total, 84 TCR samples (CD4+/CD8+ T cell populations at pre-/post-vaccination from 21 subjects) and 42 BCR samples (CD19+ populations at at pre-/post-vaccination from 21 subjects) are present in the data set.</p> <ul> <li><em><strong>Delmonte_TCR_data_84samples.rds</strong></em><br>R object with the amino acid and nucleotide sequences, VDJ gene calls, and abundances of the TCR clonotypes.</li> <li><strong><em>Delmonte_BCR_data_42samples.rds </em></strong> <br>R object with the amino acid and nucleotide sequences, VDJ gene calls, and abundances of the BCR clonotypes.</li> <li><em><strong>Delmonte_TCR_data_compact_84samples.rds</strong></em><br>R object with the amino acid sequences, VDJ gene calls, and abundances of the TCR clonotypes.</li> <li><em><strong>Delmonte_BCR_data_compact_42samples.rds </strong></em><br>R object with the amino acid sequences, VDJ gene calls, and abundances of the BCR clonotypes.</li> <li><em><strong>sampleExport_TCR.zip</strong></em><br>Compressed folder that includes the individual sample level TCR repertoire files in .tsv format.</li> <li><em><strong>sampleExport_BCR.zip</strong></em><br>Compressed folder that includes the individual sample level BCR repertoire files in .tsv format.</li> </ul> <p><br><em>Funding statement: This work was supported by the Division of Intramural Research Programs of the National Institute of Allergy and Infectious Diseases and of the National Institute of Dental and Craniofacial Research, National Institutes of Health (grant AI001270).</em><br><br></p> <p> </p>
Humoral Effect of SARS-CoV-2 mRNA vaccination with booster dose in solid tumor patients with different anticancer treatments
<p>Cancer patients are at risk for serious complications in case of SARS-CoV-2 infection. In these patients SARS-CoV-2 vaccination is strongly recommended, with the preferential use of mRNA vaccines. The antibody response in cancer patients is variable, depending on the type of cancer and antitumoral treatments. In solid tumor patients an antibody response similar to healthy subjects has been confirmed after the second dose. Only few studies explored the duration of immunization after the two doses and the effect of the third dose. In our study we explored a cohort of 273 solid tumor patients at different stages and treated with different anticancer therapies. Our analysis demonstrated that the persistence of the neutralizing antibody and the humoral response after the booster dose of vaccine was not dependent on either the tumor type, the stage or type of anticancer treatment.</p>
Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients
ClinicalTrials.gov study NCT00929019. IPD Sharing: Not stated. Countries: 1. Publications: 0.
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
ClinicalTrials.gov study NCT04977024. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Exploratory Clinical Study of Personalized mRNA Tumor Vaccine RH125 in Patients With Advanced Solid Tumors
ClinicalTrials.gov study NCT07182435. IPD Sharing: NO. Countries: 1. Publications: 0.
Lymph Node Aspiration to Decipher the Immune Response of Beta-variant Recombinant Protein Booster Vaccine (VidPrevtyn Beta, Sanofi) Compared to a Bivalent mRNA Vaccine (Comirnaty Original/Omicron BA.4
ClinicalTrials.gov study NCT05951920. IPD Sharing: NO. Countries: 1. Publications: 0.
Clinical Study of mRNA Vaccine Combined With PD-1 Inhibitor as Adjuvant Therapy for Postoperative Pancreatic Cancer
ClinicalTrials.gov study NCT06496373. IPD Sharing: NO. Countries: 1. Publications: 0.
A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19
ClinicalTrials.gov study NCT06147063. IPD Sharing: YES. Countries: 1. Publications: 0.
An Observer-blind, Cohort Randomized, Exploratory Phase 3 Study to Evaluate the Safety and Immunogenicity of Recombinant Covid-19 Vaccine, mRNA Covid-19 Vaccine and Recombinant SARS-CoV-2 Trimeric S-p
ClinicalTrials.gov study NCT05470803. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel Following mRNA COVID-19 Vaccination
ClinicalTrials.gov study NCT04880174. IPD Sharing: NO. Countries: 1. Publications: 0.
Antibodies Response to mRNA Vaccine Against Covid-19
ClinicalTrials.gov study NCT04733807. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age
ClinicalTrials.gov study NCT06864143. IPD Sharing: Not stated. Countries: 1. Publications: 0.
MRNA Neoantigen Vaccine in Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT06735508. IPD Sharing: NO. Countries: 1. Publications: 0.
Safety and Immunogenicity of ChulaCov19 BNA159 mRNA Vaccine
ClinicalTrials.gov study NCT05231369. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.